All Pharmacology articles – Page 2
-
NewsBlocking PAF receptor could offer new liver cirrhosis treatment
Spanish researchers have discovered a key inflammatory mechanism that could lead to new innovative treatments to reduce liver damage and improve vascular function in cirrhosis.
-
ArticlePeptides in practice: what it takes to advance these therapies to clinic
Peptide therapeutics are emerging as a powerful class of medicines capable of targeting diseases that challenge traditional modalities. This article reveals their rising clinical impact and the key development, safety and translational challenges that must be addressed to bring them successfully to patients.
-
NewsParkinson’s: new study rethinks dopamine’s role in movement
A new study is challenging long-held beliefs about dopamine’s role in movement, revealing new insights into how Parkinson’s disease treatments work and pointing towards more targeted future therapies.
-
NewsCBD and THC show anti-cancer effects against ovarian tumours
New research suggests cannabis compounds CBD and THC could offer a new approach to treating ovarian cancer.
-
NewsBlocking the P2X4 receptor: a potential pathway to new therapies
Researchers have discovered how to inhibit the P2X4 receptor, a key protein linked to chronic pain, inflammation and certain cancers.
-
NewsKinase inhibitors shown to accelerate protein breakdown
A new study has revealed that many kinase inhibitors – key drugs used in cancer and other diseases – also trigger the accelerated degradation of their target proteins, which could inform future therapies.
-
NewsBVRA enzyme may slow down Alzheimer’s progression
New research from Johns Hopkins Medicine reveals that the enzyme BVRA protects brain cells from oxidative stress, allowing for potential new methods for treating neurodegenerative diseases like Alzheimer’s.
-
ArticleMeet WRPRFa: the precision peptide changing how we study pain
A newly developed peptide, WRPRFa, is giving scientists a clearer view of how the acid-sensing ion channel (ASIC3) drives pain signalling.
-
ArticleWhen chemistry corrects biology: the deuterated return of a MET inhibitor
A promising MET inhibitor failed in the clinic due to human-specific metabolism. Now its deuterated analogue, DO-2, is showing that a simple isotope swap might overcome the problem.
-
ArticleFrom war rooms to launch rooms: how AI is changing the game
Within3’s Jason Smith explores how artificial intelligence is breathing new life into next-generation launch situation rooms; delivering actionable insights for pharmaceutical companies.
-
ArticleFixing failed drugs: AI solutions for toxicity in drug discovery – part 1
Why do so many drug candidates fail before reaching patients – and can AI help stop the losses? In Part 1, Layla Hosseini-Gerami of Ignota Labs outlines the scope of the toxicity problem and explains why failures often come too late to fix.
-
ArticlePain relief without the risk: why SRP-001 could change everything
A practicing surgeon turned biotech CEO is developing a novel pain medicine that could sidestep the failures of both opioids and paracetamol.
-
ArticleLB-102: Redefining schizophrenia treatment in drug discovery
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
-
NewsPromising psoriasis treatment reduces symptoms without steroids
A team of scientists from the University of Birmingham has discovered a powerful new treatment for psoriasis. The treatment uses a tripeptide that has shown steroid-level effectiveness in reducing symptoms, offering fresh hope for the long-term management of this chronic skin condition.
-
News
New hydrogel tech shows promise for treating post-traumatic osteoarthritis
Researchers from Mass General Brigham have developed a hydrogel to improve drug delivery for post-traumatic osteoarthritis (PTOA), which ensures sustained medication release, even under joint movement, addressing a major challenge in current treatments.
-
News
Alzheimer’s treatment targets root causes, not just symptoms
Porosome Therapeutics has made a groundbreaking discovery in Alzheimer’s research by targeting the disease’s molecular causes, focusing on restoring secretory and metabolic functions. This approach could not only slow progression but potentially reverse early-stage pathology.
-
ArticleNew advances in hormone replacement therapy set to transform care
Hormone replacement therapy has long been used to treat low hormone levels, but existing delivery methods struggle with poor adherence and inconsistent hormone delivery. Lisa Stehno-Bittel of Likarda and Charles Virden of VitalTE discuss a novel approach using hormone-filled microbeads in hydrogels for steady, extended release after monthly self-injections.
-
ArticleAbelacimab: the next frontier in safer anticoagulation therapy
Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.
-
ArticleEmpowering women in STEM: Navigating CMC regulatory affairs
Discover how a leader in CMC regulatory affairs is transforming drug development and inspiring the next generation of scientists.
-
ArticleObesity care gets personalised: tailoring therapies with Phenomix
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
- Previous Page
- Page1
- Page2
- Page3
- Next Page